Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_3
2
50%
Ph phase_2
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (50.0%)
Phase 32 (50.0%)

Trials by Status

unknown125%
terminated125%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
unknownphase_3

ChiCGB vs BEAM in High-risk or R/R Lymphomas

NCT05466318
completedphase_2

Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance

NCT02549586
terminatedphase_3

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

NCT02366663
completedphase_2

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

NCT00288626

Clinical Trials (4)

Showing 4 of 4 trials
NCT05466318Phase 3

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown
NCT02549586Phase 2

Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance

Completed
NCT02366663Phase 3

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

Terminated
NCT00288626Phase 2

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

Completed

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4